Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCSRT.L Regulatory News (CSRT)

  • There is currently no data for CSRT

Director/PDMR Shareholding

23 Jun 2016 11:59

RNS Number : 0964C
Consort Medical PLC
23 June 2016
Β 

Β 

Annex DTR3

Β 

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons

Β 

Β 

All relevant boxes should be completed in block capital letters.

Β 

1.

Name of the issuer

Β 

Consort Medical plc

2.

State whether the notification relates to (i) a transaction notified in accordance with DTR 3.1.2 R,

(ii) a disclosure made in accordance

LR 9.8.6R(1) or

(iii) a disclosure made in accordance with section 793 of the Companies Act (2006).

Β 

(i)

3.

Name of person discharging managerial

responsibilities/director

Β 

Ian Muir

4.

State whether notification relates to a person

connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person

Β 

Sharee Muir

5.

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a nonbeneficial

interest 1

Β 

Sharee Muir

6.

Description of shares (including class), debentures or derivatives or financial instruments relating to shares

Β 

Β 

Ordinary 10p shares

7.

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them

Β 

Sharee Muir

8.

State the nature of the transaction

Β 

Β 

Β 

Sale

9.

Number of shares, debentures or financial

instruments relating to shares acquired

Β 

N/A

10.

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)

Β 

N/A

11.

Number of shares, debentures or financial

instruments relating to shares disposed

Β 

90,000

12.

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)

Β 

0.18%

Β 

13.

Price per share or value of transaction

Β 

Β£9.85

Β 

14.

Date and place of transaction

Β 

22 June 2016 London

15.

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)

Β 

50,096 - 0.10%

Β 

16.

Date issuer informed of transaction

Β 

Β 

Β 

Β 

22 June 2016

If a person discharging managerial responsibilities has been granted options by the issuer

complete the following boxes

Β 

17.

Date of grant

Β 

Β 

18.

Period during which or date on which exercisable

Β 

Β 

19.

Total amount paid (if any) for grant of the option

20.

Description of shares or debentures involved (class and number)

Β 

Β 

21.

Exercise price (if fixed at time of grant) or

indication that price is to be fixed at the time of exercise

Β 

22.

Total number of shares or debentures over which options held following notification

Β 

23.

Any additional information

Β 

24.

Name of contact and telephone number for queries

Β 

Β 

Name of authorised official of issuer responsible for making notification

Β 

John Ilett

Β 

Β 

Date of notification 23 June 2016

Β 

Β 

Notes: This form is intended for use by an issuer to make a RIS notification required by DR 3.3.

Β 

(1)

An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.

(2)

An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.

(3)

An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.

(4)

An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
DSHBXLFLQQFEBBV
Date   Source Headline
15th Jun 20123:12 pmRNSDirector/PDMR Shareholding
14th Jun 20127:00 amRNSDirectorate
14th Jun 20127:00 amRNSPreliminary Results
6th Jun 20121:57 pmRNSBlocklisting Interim Review
1st May 201210:21 amRNSTotal Voting Rights
30th Apr 20127:00 amRNSFDA Approval Proprietary Integrated Dose Counter
20th Apr 201210:54 amRNSHolding(s) in Company
16th Apr 201211:37 amRNSBlocklisting Interim Review
28th Mar 20124:36 pmRNSHolding(s) in Company
22nd Mar 20129:58 amRNSAnnual Information Update
20th Mar 20124:25 pmRNSReplacement Interim Management Statement
20th Mar 20121:07 pmRNSInterim Management Statement
1st Mar 20129:00 amRNSTotal Voting Rights
17th Feb 201210:09 amRNSHolding(s) in Company
23rd Jan 20129:45 amRNSBlocklisting Interim Review
13th Dec 20112:25 pmRNSDirector/PDMR Shareholding
2nd Dec 20111:34 pmRNSBlocklisting Interim Review
1st Dec 20117:00 amRNSInterim results for the six months ended 31/10/11
19th Oct 20114:03 pmRNSHolding(s) in Company
17th Oct 20113:13 pmRNSHolding(s) in Company
14th Oct 20119:39 amRNSBlocklisting Interim Review
7th Oct 201112:13 pmRNSHolding(s) in Company
5th Oct 20114:47 pmRNSHolding(s) in Company
4th Oct 20117:00 amRNSSecond Nasal Drug Delivery Contract
27th Sep 20114:33 pmRNSHolding(s) in Company
26th Sep 20113:01 pmRNSHolding(s) in Company
2nd Sep 201110:21 amRNSTotal Voting Rights
1st Sep 20112:50 pmRNSResult of AGM
1st Sep 20112:47 pmRNSDirectorate Change
1st Sep 201112:40 pmRNSInterim Management Statement
1st Sep 20117:00 amRNSNasal Drug Delivery Contract
24th Aug 20114:35 pmRNSHolding(s) in Company
2nd Aug 20111:51 pmRNSDirector/PDMR Shareholding
2nd Aug 20111:47 pmRNSDirector/PDMR Shareholding
28th Jul 20119:14 amRNSAnnual Financial Report
20th Jul 20117:00 amRNSFurther re Investment in Atlas Genetics
30th Jun 20111:58 pmRNSTotal Voting Rights
24th Jun 20119:06 amRNSHolding(s) in Company
21st Jun 201112:33 pmRNSBlocklisting Interim Review
16th Jun 20117:00 amRNSPreliminary results for the year ended 30/04/11
2nd Jun 20117:00 amRNSBlocklisting Interim Review
10th May 20119:27 amRNSHolding(s) in Company
14th Apr 201110:20 amRNSBlocklisting Interim Review
4th Apr 201110:29 amRNSHolding(s) in Company
1st Apr 20111:51 pmRNSHolding(s) in Company
23rd Mar 20112:04 pmRNSAnnual Information Update
14th Mar 20117:00 amRNSInterim Management Statement
15th Feb 20114:14 pmRNSHolding(s) in Company
9th Feb 201111:15 amRNSDirectorate Change
7th Feb 20117:00 amRNSPartners with Atlas Genetics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.